The Determination and Clinical Significance of Prostaglandin E2 in Blood and Urine of Patients with Renal Colic.
This study explores the role of prostaglandin E2 (PGE2) in the etiology of urolithiasis in acute renal colic by analyzing the PGE2 levels in blood and urine throughout the clinical course of renal colic. From June 2015 to November 2017, a total of 60 patients with acute renal colic were enrolled in the study. Blood and urine samples were taken before and after administration of drug to inhibit prostaglandin synthesis; further blood and urine samples were obtained from the patients 2 weeks after their recovery. The concentration of PGE2 in blood and urine samples was determined by using a Human Prostaglandin E2 ELISA Kit. The mean concentration of PGE2 was 420 ± 50.3 ng/L in blood and 600 ± 70.1 ng/L in urine when the patients had renal colic. After drug therapy, these concentrations fell to 300 ± 40.4 ng/L in blood and 500 ± 54.5 ng/L in urine. After 2 weeks the PGE2 concentration was 220 ± 47.5 ng/L and 300 ± 50.2 ng/L in blood and urine, respectively. Compared with PGE2 levels after medication, these concentrations were significantly higher during acute renal colic (p < 0.05). The synthesis and release of PGE2 increase at the onset of renal colic, suggesting that PGE2 plays an important role in acute renal colic. Administration of a prostaglandin synthesis inhibitor is a reliable way to treat renal colic.